Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma

被引:111
作者
Kelemen, Linda E. [1 ,4 ,5 ]
Koebel, Martin [2 ,3 ]
机构
[1] Alberta Hlth Serv Canc Care, Dept Populat Hlth Res, Calgary, AB T2N 4N2, Canada
[2] Alberta Hlth Serv Calgary Lab Serv, Dept Pathol & Lab Med, Calgary, AB, Canada
[3] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada
[4] Univ Calgary, Dept Oncol, Calgary, AB, Canada
[5] Univ Calgary, Dept Med Genet, Calgary, AB, Canada
基金
加拿大健康研究院;
关键词
GYNECOLOGIC-ONCOLOGY-GROUP; MICROSATELLITE INSTABILITY; IMMUNOHISTOCHEMICAL EXPRESSION; PSEUDOMYXOMA-PERITONEI; PROTEIN EXPRESSION; GENE-EXPRESSION; KI-RAS; CLINICOPATHOLOGICAL CHARACTERISTICS; EPITHELIAL NEOPLASMS; MOLECULAR-FEATURES;
D O I
10.1016/S1470-2045(11)70058-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mucinous carcinomas are uncommon histological types that affect several organ sites. Primary mucinous carcinomas of the ovary are distinct from other ovarian carcinoma types, but they can pose a particular challenge for correct diagnosis from metastases, which most usually originate from the colorectum. Correct diagnosis is the mainstay of treatment, because standard practice states that protocols are tailored to the primary organ site. Little is known of mutational alterations in primary and metastatic mucinous carcinomas of the ovary, and few markers exist that can discriminate between them. We reviewed commonalities between ovarian and colorectal mucinous carcinomas with respect to aetiology, molecular alterations, differential diagnosis, and implications for treatment. Although primary mucinous carcinomas of the ovary and colorectum share similar mutational patterns and unfavourable outcomes at advanced stage, compared with their non-mucinous counterparts, important differences exist with respect to mucin localisation and specific molecular alterations. Technologies-eg, next-generation sequencing-could aid identification of additional driver molecular changes that will help clarify the relation between mucinous carcinomas from different organ sites. Perhaps, then, we can consider moving towards testing and adoption of therapeutic approaches tailored to molecular characteristics of mucinous carcinomas, irrespective of organ site, so patients' survival can be optimised.
引用
收藏
页码:1071 / 1080
页数:10
相关论文
共 79 条
[1]   HER2, TOP2A, CCND1, EGFR and c-MYC oncogene amplification in colorectal cancer [J].
Al-Kuraya, Khawla ;
Novotny, Hedvika ;
Bavi, Prashant ;
Siraj, Abdul K. ;
Uddin, Shahab ;
Ezzat, Adnan ;
Al Sanea, Nasser ;
Al-Dayel, Fouad ;
Al-Mana, Hadeel ;
Sheikh, Salwa S. ;
Mirlacher, Martina ;
Tapia, Coya ;
Simon, Ronald ;
Sauter, Guido ;
Terracciano, Luigi ;
Tornillo, Luigi .
JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (07) :768-772
[2]  
[Anonymous], 2000, WHO CLASSIFICATION T
[3]   Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal Cancer [J].
Baba, Yoshifumi ;
Nosho, Katsuhiko ;
Shima, Kaori ;
Freed, Ellen ;
Irahara, Natsumi ;
Philips, Juliet ;
Meyerhardt, Jeffrey A. ;
Hornick, Jason L. ;
Shivdasani, Ramesh A. ;
Fuchs, Charles S. ;
Ogino, Shuji .
CLINICAL CANCER RESEARCH, 2009, 15 (14) :4665-4673
[4]   Mucinous But Not Clear Cell Histology Is Associated With Inferior Survival in Patients With Advanced Stage Ovarian Carcinoma Treated With Platinum-Paclitaxel Chemotherapy [J].
Bamias, Aristotle ;
Psaltopoulou, Theodora ;
Sotiropoulou, Maria ;
Haidopoulos, Dimitrios ;
Lianos, Evangelos ;
Bournakis, Evangelos ;
Papadimitriou, Christos ;
Rodolakis, Alexandros ;
Vlahos, George ;
Dimopoulos, Meletius A. .
CANCER, 2010, 116 (06) :1462-1468
[5]   Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy [J].
Catalano, V. ;
Loupakis, F. ;
Graziano, F. ;
Torresi, U. ;
Bisonni, R. ;
Mari, D. ;
Fornaro, L. ;
Baldelli, A. M. ;
Giordani, P. ;
Rossi, D. ;
Alessandroni, P. ;
Giustini, L. ;
Silva, R. R. ;
Falcone, A. ;
D'Emidio, S. ;
Fedeli, S. L. .
BRITISH JOURNAL OF CANCER, 2009, 100 (06) :881-887
[6]   Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with β-catenin [J].
Chou, YY ;
Jeng, YM ;
Kao, HL ;
Chen, TJ ;
Mao, TL ;
Lin, MC .
HISTOPATHOLOGY, 2003, 43 (02) :151-156
[7]   Incidence and survival of mucinous adenocarcinoma of the colorectum: A population-based study from an Asian country [J].
Du, WB ;
Mah, JTL ;
Lee, J ;
Sankila, R ;
Sankaranarayanan, R ;
Chia, KS .
DISEASES OF THE COLON & RECTUM, 2004, 47 (01) :78-85
[8]   Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women [J].
Engeland, A ;
Tretli, S ;
Austad, G ;
Bjorge, T .
CANCER CAUSES & CONTROL, 2005, 16 (08) :987-996
[9]   Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [J].
Ferlay, Jacques ;
Shin, Hai-Rim ;
Bray, Freddie ;
Forman, David ;
Mathers, Colin ;
Parkin, Donald Maxwell .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2893-2917
[10]   Colorectal Cancer Risk Prediction Tool for White Men and Women Without Known Susceptibility [J].
Freedman, Andrew N. ;
Slattery, Martha L. ;
Ballard-Barbash, Rachel ;
Willis, Gordon ;
Cann, Bette J. ;
Pee, David ;
Gail, Mitchell H. ;
Pfeiffer, Ruth M. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :686-693